News
CEO of Novo Nordisk, maker of Wegovy, is stepping down
Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of directors, citing “recent market challenges” and a steep decline in the company’s share price.
Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...
Everyday Health on MSN2d
Zepbound Beats Wegovy for Weight Loss in First Head-to-Head TrialIn a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
One weight loss injection has been branded more effective than another, after scientists carry out the first ever ...
The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...
Axios on MSN1d
Wegovy maker Novo Nordisk CEO to step downNovo Nordisk CEO Lars Fruergaard Jørgensen is stepping down as the Danish drug giant faces increased competition for its ...
A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...
Novo Nordisk, the company that makes the weight loss drugs Ozempic and Wegovy, is abruptly ousting its chief executive, Lars Fruergaard Jørgensen, over concerns the firm is losing ground in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback